梁凯威 教授

职称职务：教授、 博士/硕士研究生导师、泰康生命医学中心PI 、常务副院长、国家级人才计划入选者

招生专业：生理学、病理生理学
研究方向：基因转录、表观遗传学、血液肿瘤
实验室位置：基础医学院3号楼4楼
Email： kwliang@whu.edu.cn

学习经历

2003-2007 武汉大学，生物学基地班，学士

2007-2009 武汉大学生命科学学院，生物化学与分子生物学，硕士

2012-2016 美国Stowers医学研究所，博士

主要工作经历与任职

2011.06--2011.12 美国Stowers医学研究所Predoctoral Researcher

2012.01--2016.05 美国Stowers医学研究所博士研究生

2016.07--2018.03 美国西北大学Feinberg医学院博士后

2018.03--至今  武汉大学基础医学院教授（其间：2018.05-2018.10美国西北大学Feinberg医学院访问学者）

目前主要科学研究领域和兴趣

课题组以染色体易位所导致的白血病为疾病模型，主要利用蛋白质组学和功能基因组学方法研究遗传变异所导致的造血干细胞恶性转化为白血病的发病机制，探索发病过程中的转录成瘾机制以及鉴定全新的分子治疗靶标和靶向治疗策略。

课题组研究方向包括：

1. 遗传变异和表观遗传变异所导致的血液肿瘤的发病机制和靶向治疗;

2. 转录成瘾机制和新靶标鉴定;

3. 基于转录成瘾机制的小分子靶向药物开发。

教学情况

本科生课程：“生理学”，“病理生理学”，“损伤与反应”，“生物医学技术前沿”， “医学与健康”， “医学前沿进展”

研究生课程: “生物医学前沿进展”

2017 Chromatin, Epigenetics and Gene Expression, CSHL

2013 Eukaryotic Gene Expression Course, CSHL

获批资助项目

国家自然科学基金委优秀青年科学基金，主持，资助期：2022-2024

国家自然科学基金委面上项目，主持，资助期：2022-2025

科技部“干细胞与转化”重点研发计划青年项目，主持，资助期：2019-2023

湖北省医学青年第一层次资助 ，主持，资助期：2019-2023

第十四批海外高层次计划“青年项目”优先资助，主持，资助期：2018-2021

武汉大学人才引进项目，主持，资助期：2018-2021

近期代表性论文

After 2019:

1. Qiu M., Yin Z., Wang H., Lei L., Li C., Cui Y., Dai R., Yang P., Xiang Y., Li Q., Lv J., Hu Z., Chen M., Zhou H., Fang, P.*, Xiao R.*, Liang K.* CDK12 and Integrator-PP2A Complex Modulates LEO1 Phosphorylation for Processive Transcription Elongation. Science Advances 2023.

2. Wang D., Yin Z., Wang H., Wang L., Li T., Xiao R., Xie T., Han R., Dong R., Liu H.*, Liang K.*, Qing G.* The super elongation complex drives transcriptional addiction in MYCN-amplified neuroblastoma. Science Advances 2023, 9:eadf0005.

3. Li C., Yin Z., Xiao R., Huang B., Cui Y., Wang H., Xiang Y., Wang L., Lei L., Ye J., Li T., Zhong Y., Guo F., Xia Y., Fang P. *, Liang K.* G-quadruplexes sense natural porphyrin metabolites for regulation of gene transcription and chromatin landscapes. Genome Biology, 2022, 23:259

4. H. Wang, C. Li, K. Liang*. Genome-Wide Native R-Loop Profiling by R-Loop Cleavage Under Targets and Tagmentation (R-Loop CUT&Tag). Methods Mol. Boil: R-Loops, 2022 (Bookchapter)

5. X. Lan, S. Ding, T. Zhang, Y. Yi, C. Li, W. Jin, J. Chen, K. Liang, H. Wang, W. Jiang. PCGF6 controls neuroectoderm specification of human pluripotent stem cells by activating SOX2 expression. Nature Communications, 2022. 4601 (13)

6. C. Li#, H. Wang#, Z. Yin#, P. Fang#, R. Xiao, Y. Xiang, W. Wang, Q. Li, B. Huang, J. Huang, K. Liang*. Ligand-induced Native G-quadruplexes Stabilization Impairs Transcription Initiation. Genome Research, 2021. 31: 1546-1560 (封面论文)

7. K. Wang, H. Wang, C. Li, Z. Yin, R. Xiao, Q. Li, Y. Xiang, W. Wang, J. Huang, L. Chen, P. Fang*, K. Liang*. Genomic Profiling of Native R-loops with a DNA-RNA Hybrid Recognition Sensor. Science Advances, 2021. 7: eabe3516

8. Zheng. H., Qi. Y., Hu. S., Cao. X., Xu. C., Yin. Z., Chen. X., Li. Y., Liu. W., Li. J., Wang. J., Wei, G., Liang, K., Chen. F., and Xu. Y. Identification of Integrator-PP2A complex (INTAC), an RNA polymerase II phosphatase. Science, 2020. 370.

9. Cao, K., Ugarenko, M., Ozark, P.A., Wang, J., Marshall, S.A., Rendleman, E.J., Liang, K., Wang, L., Zou, L., Smith, E.R., et al. DOT1L-controlled cell-fate determination and transcription elongation are independent of H3K79 methylation. Proc Natl Acad Sci U S A, 2020. 117, 27365-27373.

Before 2019:

10. K. Liang, E. R. Smith, Y. Aoi, K. L. Stoltz, H. Katagi, A. R. Woodfin, E. J. Rendleman, S. A. Marshall, D. C. Murray, L.Wang, P. A. Ozark, R.K. Mishra, R. Hashizume, G. E. Schiltz, and A. Shilatifard, Targeting Processive Transcription Elongation Via SEC Disruption For MYC-induced Cancer Therapy. Cell, 2018. 175(3) p. 766-779 e17.

11. A. Volk, K. Liang, J. Zhao, X. Li, M.Bulic, S. Marshall, J.W. Taub, Y. Ge, S. Malinge, E. Bartom, A. Shilatifard, and J.D Crispino, A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemic Pathogenesis. Cancer Cell, 2018. 34: p. 707-724.

12. K. Liang, A. G. Volk, J. S. Haug, S. A. Marshall, A. R. Woodfin, E. T. Bartom, J. M. Gilmore, L. Florens, M. P. Washburn, K. D. Sullivan, J. M. Espinosa, J. Cannova, J. Zhang, E. R. Smith, J. D. Crispino, and A. Shilatifard, Therapeutic Targeting of Mll Degradation Pathways in Mll-Rearranged Leukemia. Cell, 2017. 168(1-2): p. 59-72 e13.

13. Wang, L., Collings, C.K., Zhao, Z., Cozzolino, K.A., Ma, Q., Liang, K., Marshall, S.A., Sze, C.C., Hashizume, R., Savas, J.N., et al. A cytoplasmic COMPASS is necessary for cell survival and triple-negative breast cancer pathogenesis by regulating metabolism. Genes Dev, 2017. 31, 2056-2066.

14. Ebmeier, C.C., Erickson, B., Allen, B.L., Allen, M.A., Kim, H., Fong, N., Jacobsen, J.R., Liang, K., Shilatifard, A., Dowell, R.D., et al. Human TFIIH Kinase CDK7 Regulates Transcription-Associated Chromatin Modifications. Cell Reports, 2017. 20, 1173-1186.

15. K. Liang, A. R. Woodfin, B. D. Slaughter, J. R. Unruh, A. C. Box, R. A. Rickels, X. Gao, J. S. Haug, S. L. Jaspersen, and A. Shilatifard, Mitotic Transcriptional Activation: Clearance of Actively Engaged Pol Ii Via Transcriptional Elongation Control in Mitosis. Molecular Cell, 2015. 60(3): p. 435-45. (封面论文)

16. K. Liang, X. Gao, J. M. Gilmore, L. Florens, M. P. Washburn, E. Smith, and A. Shilatifard, Characterization of Human Cyclin-Dependent Kinase 12 (Cdk12) and Cdk13 Complexes in C-Terminal Domain Phosphorylation, Gene Transcription, and Rna Processing. Mol Cell Biol, 2015. 35(6): p. 928-38.

17. Herz, H.M., Mohan, M., Garruss, A.S., Liang, K., Takahashi, Y.H., Mickey, K., Voets, O., Verrijzer, C.P., and Shilatifard, A. Enhancer-associated H3K4 monomethylation by Trithorax-related, the Drosophila homolog of mammalian Mll3/Mll4. Genes Dev, 2012. 26, 2604-2620.

18. K. Liang#, L. Yang#, C. Yin, Z. Xiao, J. Zhang, Y. Liu, and J. Huang, Estrogen Stimulates Degradation of Beta-Amyloid Peptide by up-Regulating Neprilysin. J Biol Chem, 2010. 285(2): p. 935-42.

专利申请：

1. A. Shilatifard, K. Liang, E. R. Smith, and G. E. Schiltz (2020), Therapeutic Targeting of Interleukin-1 Receptor-Associated Kinase 4 (Irak4) in Cancers Characterized by Rearrangements in the Mixed Lineage Leukemia Gene (Mll-R). 2020, US Patent App. 15/497,783. （专利）

2. A. Shilatifard, K. Liang, E. R. Smith, G. E. Schiltz, R.K. Mishra, and L. Stoltz (2021), Small Molecules for Disrupting the Super Elongation Complex and Inhibiting Transcription Elongation for Cancer Therapy. 2021, US Patent App. 16/981,654 （专利）

3. 一种R-环结合蛋白GST-His6-1/2XHBD及全基因组R-环的检测方法, 2020-9-10, 中国, 专利号：ZL 2020 1 0946487.8 （专利）

4. 靶向CBFβ-SMMHC蛋白的PROTAC类化合物及其制备方法与应用, 2022-8-8, 中国, 申请号：202210943598.2 （专利）

备注：欢迎有志于从事表观遗传学和肿瘤靶向治疗研究的优秀博士后加入团队！